PT  - JOURNAL ARTICLE
AU  - Lederman, Lynne
TI  - SC Ibalizumab Warrants Further Study for Preventing HIV-1 Infection
DP  - 2014 Dec 01
TA  - MD Conference Express
PG  - 9--10
VI  - 14
IP  - 28
4099  - http://mdc.sagepub.com/content/14/28/9.short
4100  - http://mdc.sagepub.com/content/14/28/9.full
AB  - Among the strategies being explored to prevent infection with human immunodeficiency virus type 1 is ibalizumab, a humanized monoclonal antibody that binds to CD4 domain 2 and blocks the entry of HIV-1 into CD4-positive T cells. This article discusses the Safety Study of Ibalizumab Subcutaneous Injection in Healthy Volunteers (TMB-108) [NCT01292174] results of a study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of subcutaneous injections of ibalizumab.